Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 44c; Offers Guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.33 +0.95%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
VIPS, QFIN, STRT, More
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
VIPS, QFIN, STRT, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($1.04), $0.44 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $50.52 million versus the consensus estimate of $61.78 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2026 revenue of $240-290 million, versus the consensus of $262.1 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Upgrades Smoore International Holdings Limited (6969:HK) (SMORF) to Buy
- Canaccord Upgrades ARB Corp Ltd (ARB:AU) to Buy
- Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
